Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
about
ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.Heterogeneity of excision repair cross-complementation group 1 gene expression in non-small-cell lung cancer patients.MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer.Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution.
P2860
Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Prognostic potential of ERCC1 ...... N2 non-small cell lung cancer.
@en
type
label
Prognostic potential of ERCC1 ...... N2 non-small cell lung cancer.
@en
prefLabel
Prognostic potential of ERCC1 ...... N2 non-small cell lung cancer.
@en
P2093
P2860
P356
P1476
Prognostic potential of ERCC1 ...... N2 non-small cell lung cancer.
@en
P2093
P2860
P2888
P356
10.1186/1749-8090-8-149
P577
2013-06-10T00:00:00Z
P5875
P6179
1003875983